These RTKs are known to activate multiple downstream signaling cascades, including PI3K/AKT, RAS/MAPK, and JAK/STAT, all of which are frequently dysregulated in HCC and contribute to resistance to conventional therapies [20]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.